Lundbeck and Otsuka announce U.S. Food and Drug Administration (FDA) approval of sNDA for Rexulti® (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer's Disease
Rexulti is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimers disease Valby, Denmark, May 11, 2023 - H. Lundbeck A/S and... | May 11, 2023
United States Thomas Mikkel Mortensen Jeffrey Gilbert Robert Murphy Deborah Dunsire Palle Holm Olesen
Source: marketscreener.com